CONTRAVE
Chronic Weight Management
ApprovedActive
Key Facts
About Currax Pharmaceuticals
Currax Pharmaceuticals is a commercial-stage biopharma company that has built a portfolio of marketed products, most notably the obesity drug CONTRAVE®. The company leverages a business model of acquiring and commercializing established or niche pharmaceutical products, with a significant strategic focus on the obesity treatment market. Under CEO George Hampton, Currax emphasizes direct-to-patient platforms, educational campaigns, and ensuring supply chain resilience to compete in the dynamic chronic disease landscape.
View full company profileOther Chronic Weight Management Drugs
| Drug | Company | Phase |
|---|---|---|
| QSIVA®/QSYMIA® | VIVUS | Approved |
| Generic Semaglutide Injection | Sun Pharmaceutical | ANDA Approved |